Association between arachidonate lipoxygenase 15,c.-292 C > T gene polymorphism and non-cystic fibrosis bronchiectasis in children: a pilot study on the effects on airway lipoxin A4 and disease phenotype.
ALOX-15 polymorphism
BAL
Bronchiectasis
Lipoxin A4
Journal
Italian journal of pediatrics
ISSN: 1824-7288
Titre abrégé: Ital J Pediatr
Pays: England
ID NLM: 101510759
Informations de publication
Date de publication:
29 Apr 2024
29 Apr 2024
Historique:
received:
20
09
2023
accepted:
07
04
2024
medline:
30
4
2024
pubmed:
30
4
2024
entrez:
29
4
2024
Statut:
epublish
Résumé
Persistent airway inflammation is a central feature of bronchiectasis. Arachidonate 15-lipoxygenase (ALOX-15) controls production of endogenous lipid mediators, including lipoxins that regulate airway inflammation. Mutations at various positions in ALOX-15 gene can influence airway disease development. We investigated association between ALOX-15,c.-292 C > T gene polymorphism and bronchiectasis unrelated to cystic fibrosis in Egyptian children. Also, lipoxin A4 (LXA4) level in bronchoalveolar lavage (BAL) was studied in relation to polymorphism genotypes and disease phenotypes determined by clinical, pulmonary functions, and radiological severity parameters. This was an exploratory study that included 60 participants. Thirty children with non-cystic fibrosis bronchiectasis (NCFB) were compared with 30 age and sex-matched controls. ALOX-15,c.-292 C > T polymorphism was genotyped using TaqMan-based Real-time PCR. LXA4 was measured in BAL using ELISA method. There was no significant difference between patients and controls regarding ALOX-15,c.-292 C > T polymorphism genotypes and alleles (OR = 1.75; 95% CI (0.53-5.7), P = 0.35) (OR = 1; 95% CI (0.48-2), p = 1). BAL LXA4 level was significantly lower in patients, median (IQR) of 576.9 (147.6-1510) ng/ml compared to controls, median (IQR) of 1675 (536.8-2542) (p = 0.002). Patients with severe bronchiectasis had a significantly lower LXA4 level (p < 0.001). There were significant correlations with exacerbations frequency (r=-0.54, p = 0.002) and FEV1% predicted (r = 0.64, p = 0.001). Heterozygous CT genotype carriers showed higher LXA4 levels compared to other genotypes(p = 0.005). Low airway LXA4 in children with NCFB is associated with severe disease phenotype and lung function deterioration. CT genotype of ALOX-15,c.-292 C > T polymorphism might be a protective genetic factor against bronchiectasis development and/or progression due to enhanced LXA4 production.
Sections du résumé
BACKGROUND
BACKGROUND
Persistent airway inflammation is a central feature of bronchiectasis. Arachidonate 15-lipoxygenase (ALOX-15) controls production of endogenous lipid mediators, including lipoxins that regulate airway inflammation. Mutations at various positions in ALOX-15 gene can influence airway disease development. We investigated association between ALOX-15,c.-292 C > T gene polymorphism and bronchiectasis unrelated to cystic fibrosis in Egyptian children. Also, lipoxin A4 (LXA4) level in bronchoalveolar lavage (BAL) was studied in relation to polymorphism genotypes and disease phenotypes determined by clinical, pulmonary functions, and radiological severity parameters.
METHODS
METHODS
This was an exploratory study that included 60 participants. Thirty children with non-cystic fibrosis bronchiectasis (NCFB) were compared with 30 age and sex-matched controls. ALOX-15,c.-292 C > T polymorphism was genotyped using TaqMan-based Real-time PCR. LXA4 was measured in BAL using ELISA method.
RESULTS
RESULTS
There was no significant difference between patients and controls regarding ALOX-15,c.-292 C > T polymorphism genotypes and alleles (OR = 1.75; 95% CI (0.53-5.7), P = 0.35) (OR = 1; 95% CI (0.48-2), p = 1). BAL LXA4 level was significantly lower in patients, median (IQR) of 576.9 (147.6-1510) ng/ml compared to controls, median (IQR) of 1675 (536.8-2542) (p = 0.002). Patients with severe bronchiectasis had a significantly lower LXA4 level (p < 0.001). There were significant correlations with exacerbations frequency (r=-0.54, p = 0.002) and FEV1% predicted (r = 0.64, p = 0.001). Heterozygous CT genotype carriers showed higher LXA4 levels compared to other genotypes(p = 0.005).
CONCLUSIONS
CONCLUSIONS
Low airway LXA4 in children with NCFB is associated with severe disease phenotype and lung function deterioration. CT genotype of ALOX-15,c.-292 C > T polymorphism might be a protective genetic factor against bronchiectasis development and/or progression due to enhanced LXA4 production.
Identifiants
pubmed: 38685084
doi: 10.1186/s13052-024-01654-5
pii: 10.1186/s13052-024-01654-5
doi:
Substances chimiques
Arachidonate 15-Lipoxygenase
EC 1.13.11.33
lipoxin A4
0
Lipoxins
0
ALOX15 protein, human
EC 1.13.11.33
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
90Informations de copyright
© 2024. The Author(s).
Références
Expert Rev Clin Immunol. 2021 Jun;17(6):681-690
pubmed: 33793355
Radiology. 1991 Jun;179(3):783-8
pubmed: 2027992
J Immunol. 2003 Dec 15;171(12):6856-65
pubmed: 14662892
Eur Respir J. 2000 Jan;15(1):217-31
pubmed: 10678650
Children (Basel). 2022 Sep 19;9(9):
pubmed: 36138729
Braz Dent J. 2017 Mar-Apr;28(2):140-147
pubmed: 28492741
J Thorac Dis. 2021 Mar;13(3):1495-1506
pubmed: 33841942
Comput Struct Biotechnol J. 2013 Dec 06;6:e201303018
pubmed: 24688726
Nat Immunol. 2004 Apr;5(4):388-92
pubmed: 15034576
Nat Immunol. 2001 Jul;2(7):612-9
pubmed: 11429545
Pediatr Pulmonol. 2016 May;51(5):450-69
pubmed: 26840008
Clin Exp Allergy. 2007 Oct;37(10):1494-501
pubmed: 17883729
Front Pediatr. 2017 May 29;5:123
pubmed: 28611970
Biomed Res Int. 2015;2015:781087
pubmed: 25866809
BMC Pulm Med. 2020 Jun 16;20(1):172
pubmed: 32546272
Hum Mutat. 2006 Jan;27(1):78-87
pubmed: 16320347
Thorax. 2022 Oct;77(10):960-967
pubmed: 34789559
Thorax. 2002 Jan;57(1):15-9
pubmed: 11809984
BMC Pediatr. 2014 Dec 10;14:4
pubmed: 25492164
Eur Respir Rev. 2020 Jan 29;29(155):
pubmed: 31996354
Pediatr Pulmonol. 2007 Apr;42(4):362-9
pubmed: 17351928
Eur Respir J. 2021 Aug 26;58(2):
pubmed: 33542057
Ital J Pediatr. 2021 Jun 16;47(1):138
pubmed: 34134742
Front Immunol. 2021 Apr 23;12:658840
pubmed: 33968061
Medicina (Kaunas). 2012;48(6):292-8
pubmed: 22885362
Biomed Res Int. 2022 Sep 25;2022:4589191
pubmed: 36199753
Eur Respir J. 2005 Nov;26(5):948-68
pubmed: 16264058
Eur Respir J. 2014 Aug;44(2):394-404
pubmed: 24696116
Thorax. 2004 Mar;59(3):231-6
pubmed: 14985560
J Microbiol Immunol Infect. 2020 Dec;53(6):1014-1020
pubmed: 32094076
Inflammation. 2022 Oct;45(5):1950-1967
pubmed: 35438373
Pediatr Neonatol. 2020 Jun;61(3):255-262
pubmed: 31672477
Ann Thorac Med. 2016 Jan-Mar;11(1):55-9
pubmed: 26933458
Clin Chem Lab Med. 2007;45(4):487-92
pubmed: 17439326
Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13375-80
pubmed: 10557328
Allergy Asthma Immunol Res. 2021 Sep;13(5):684-696
pubmed: 34486255
Am J Respir Crit Care Med. 2019 Oct 15;200(8):e70-e88
pubmed: 31613151
J Exp Med. 1996 Apr 1;183(4):1633-43
pubmed: 8666921